非諾貝特

OBJECTIVEA method for the determination of dissolution of fenofibrate chewable tablets in vitro was established. 目的:建立非諾貝特咀嚼片體外溶出度試驗(yàn)測(cè)定方法。

The risk of a first amputation was 36 percent lower among people taking fenofibrate than those taking the placebo. 初次截肢的風(fēng)險(xiǎn)非諾貝特組較安慰劑組降低了36%25。

Objective: To study the effects of Provastatin with Micronized Fenofibrate on HDL C and LDL C in old patients. 目的:研究普伐他汀和微粒化非諾貝特對(duì)老年人高密度脂蛋白膽固醇(HDL-C)和低密度脂蛋白膽固醇(LDL-C)的作用。

Fenofibrate significantly reduced CVD events in those with low HDL cholesterol or hypertension. 非諾貝特顯著降低HDL膽固醇水平較低患者或高血壓患者的CVD事件。

CONCLUSION:micronised fenofibrate is bene ficial on adjusting lipid level and blood viscosity. 結(jié)論：微粒化非諾貝特能有效降低高血脂，同時(shí)明顯改善了病人的高粘血癥。